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Abstract
The EBV-encoded latent membrane protein 1 (LMP1) functions as a constitutive active form of tumor necrosis factor
receptor (TNFR) and activates multiple downstream signaling pathways similar to CD40 signaling in a ligand-independent
manner. LMP1 expression in EBV-infected cells has been postulated to play an important role in pathogenesis of
nasopharyngeal carcinoma. However, variable levels of LMP1 expression were detected in nasopharyngeal carcinoma. At
present, the regulation of LMP1 levels in nasopharyngeal carcinoma is poorly understood. Here we show that LMP1 mRNAs
are transcribed in an EBV-positive nasopharyngeal carcinoma (NPC) cell line (C666-1) and other EBV-negative
nasopharyngeal carcinoma cells stably re-infected with EBV. The protein levels of LMP1 could readily be detected after
incubation with proteasome inhibitor, MG132 suggesting that LMP1 protein is rapidly degraded via proteasome-mediated
proteolysis. Interestingly, we observed that Id1 overexpression could stabilize LMP1 protein in EBV-infected cells. In
contrary, Id1 knockdown significantly reduced LMP1 levels in cells. Co-immunoprecipitation studies revealed that Id1
interacts with LMP1 by binding to the CTAR1 domain of LMP1. N-terminal region of Id1 is required for the interaction with
LMP1. Furthermore, binding of Id1 to LMP1 suppressed polyubiquitination of LMP1 and may be involved in stabilization of
LMP1 in EBV-infected nasopharyngeal epithelial cells.
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Introduction
Epstein-Barr virus (EBV, also categorized as human herpesvirus
type 4) is the first human oncogenic DNA virus isolated from
Burkitt’s lymphoma capable to transform B cells in vitro [1]. EBV
was later shown to be a prototype of gamma herpesvirus that
infects the majority of population worldwide. After infection, most
people carry the virus in their memory B cells in latent stage. EBV
infection is associated with specific types of human malignancies,
for example Burkitt’s lymphoma, Hodgkin’s lymphoma, nasopha-
ryngeal carcinoma and gastric carcinoma [2]. The underlying
oncogenic mechanisms of EBV are still poorly understood and
pre-existing genetic alterations in the infected host cells are
believed to be involved.
Examination of the expression profile of EBV genes in EBV-
related malignancies and EBV-derived cell lines have defined four
major types of EBV latent infection: Latency 0, 1, 2 and 3 each
with distinct EBV gene expression. Nasopharyngeal carcinoma are
shown to exhibit type II latency infection and the major EBV
genes expressed are EBNA1, EBER, LMP1, LMP2A, LMP2B,
BARF1 and BARTs. The LMP1 is well-documented to be an
important oncoprotein of EBV. It is a transmembrane protein
which localizes at cholesterol-rich lipid raft [3,4]. LMP1 functions
as constitutive active form of tumor necrosis factor receptor
(TNFR) and activates multiple downstream signaling pathways
similar to CD40 signaling mostly via its C-terminal activation
domains (CTAR): CTAR1, CTAR2 and CTAR3 [5].
Using nested RT-PCR, more than 90% of nasopharyngeal
carcinoma is shown to be positive in LMP1 expression which
supports a role of LMP1 in the pathogenesis of nasopharyngeal
carcinoma [6]. Intriguingly, LMP1 protein was only detected at
low level in NPC tissues and generally absent in EBV-infected
nasopharyngeal carcinoma cells [7]. The oncogenic action of
LMP1 may play a more important role at early stage of
development of nasopharyngeal carcinoma. Presumably, the levels
of LMP1 in EBV-infected cells are tightly regulated by host
cellular factors. Earlier studies have reported that intracellular
signaling events could modulate LMP1 expression. Chen et al
reported that STAT3 could upregulate LMP1 transcript through
activating the TR, LMP1 ED-L1 and TR promoters [8]. Recently,
Johansson et al showed that p38 activation could promote LMP1
expression in lymphoblastoid cell lines (LCL) [9]. Goormachtigh et
al found that LMP1 promoter activity was inhibited by NF-
kappaB signaling [10]. However, an opposite conclusion was
drawn by Demetriades et al showing that NF-kappaB could
activate LMP1 pomoter activity [11]. Independently, using DNA
affinity purification and chromatin immunoprecipitation assay,
Johansson et al showed that the NK-kB p50-p50 homodimers and
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upregulate LMP1 expression [12]. The discrepancy of the findings
has yet to be resolved. LMP1 expression was also shown to be
targeted by BART microRNAs and negatively regulated LMP1
expression [13]. LMP1 has also been shown to be target of
degradation via ubiquitin-mediated proteasome degradation
pathway [14]. At present, very little information is available on
the regulation of degradation rate and stability of LMP1 protein
levels in cells.
The inhibitor of DNA binding/differentiation (Id), is a family of
helix-loop-helix (HLH) proteins described by Robert Benezra in
1990 [15]. These proteins were characterized as HLH proteins
lacking the DNA-binding domain. There are four members of Ids
in vertebrates, known as Id1, Id2, Id3 and Id4. They were found
to play important roles in development and tumorigenesis. Id1 is
often found to be overexpressed in cancer cells and contributes to
malignant properties of cancer cells including cell proliferation,
invasion and angiogenesis [16]. We had previously reported that
LMP1 could upregulate Id1 expression in epithelial cells [17]
which was confirmed by independent studies [18,19]. These
findings imply Id1 is a downstream effector of LMP1 which
supports the oncogenic role of LMP1. Its involvement in the
regulation of LMP1 protein in cells has not been examined.
In this study, we had examined the LMP1 protein levels in
different EBV-infected cell lines. Consistent with previous reports,
the protein levels of LMP1 were low among all EBV-infected cells
examined. However, proteasome inhibitor could effectively
stabilize LMP1 protein in all EBV-infected cells. Interestingly,
we observed that overexpression of Id1 resulted in higher LMP1
protein level in EBV-infected cells. Detail examination revealed
that Id1 could interact and stabilize LMP1 by suppressing LMP1
polyubiquitination. We postulate that Id1 overexpression may play
a role in modulating LMP1 protein levels in EBV-infected
nasopharyngeal carcinoma cells.
Results
Detection of LMP1 transcripts in EBV-infected human
epithelial cells
Previous reports have shown that LMP1 protein levels were
either low or undetectable by Western blotting analysis in EBV-
infected human epithelial cells in culture [7]. To examine if LMP1
is transcribed in all EBV-infected cells under studies, we extracted
total RNA from different EBV-infected cell lines and examined for
the presence of LMP1 transcripts. The LMP1 transcripts were
readily detected in C666-1 which is an EBV-positive nasopharyn-
geal carcinoma cell line [7], and other cell lines infected with EBV
including NP460-hTERT-EBV (hTERT-immortalized nasopha-
ryngeal epithelial cells) [20], HONE1-EBV (nasopharyngeal
carcinoma cells), CNE2-EBV (nasopharyngeal carcinoma cells),
HK1-EBV (nasopharyngeal carcinoma cells) and AGS-EBV
(gastric carcinoma cells). EBV infection of these cell lines were
previously established in our laboratories [21,22,23] (Fig. 1A). The
HONE1 and CNE2 are commonly used NPC cell lines which
were initially EBV positive when established from patient biopsies
but lost their EBV genomes upon prolonged propagation [24,25].
The HK1 was isolated from a well-differentiated EBV-negative
nasopharyngeal carcinoma [26]. The AGS was isolated from
gastric adenocarcinoma [27].
As a positive control for LMP1 transcription, tetradecanoyl
phorbol acetate (TPA) treated-Akata cells were used [28]. LMP1
expression is known to be induced in TPA-treated Akata cells
which activate lytic infection of EBV. In consistent with earlier
report [7], high level of LMP1 transcripts was detected in C666-1.
The highest level of LMP1 transcripts was also detected in Akata
cells after TPA treatment. The data indicates that LMP1 is
regularly transcribed in all EBV-infected cell lines examined.
Accumulation of LMP1 in EBV-infected cells treated with
proteasome inhibitors
Consistent with previous reports [7,29,30], the LMP1 protein
levels in C666-1 and the established EBV-infected nasopharyngeal
epithelial cell lines were either low or undetectable by Western
blotting analysis (Fig. 1B and 1C). Previous study from our
laboratory revealed that EBV has established type II latency
infection in these EBV-infected cell lines and LMP1 transcripts
were present [31]. We explore if failure to detect LMP1 protein by
Western blotting analysis was a result of rapid degradation of
LMP1 proteins in EBV-infected epithelial cells. We treated EBV-
infected cells with a proteasome inhibitor, MG132, to examine if
LMP1 could be accumulated in the treated cells. We observed that
LMP1 protein becomes detectable in C666-1 cells by Western
blotting after MG132 treatment in a time-dependent manner
(Fig. 1B). Furthermore, LMP1 protein could also be detected by
Western blotting in other EBV-infected cell lines after treatment
with MG132 (Fig. 1C). These results indicated that LMP1 is
rapidly degraded in EBV-infected cells despite the active
transcription of the LMP1 gene.
In addition to proteasomal degradation, the LMP1 may also be
degraded by lysosomal protein degradation pathway which is
commonly involved in the turnover of plasma membrane-bound
receptors [32,33]. LMP1 is a membrane-bound protein which
localizes in lipid rafts and may be subjected to lysosomal
degradation. We then sought to determine if lysosomal degrada-
tion pathway is also involved in LMP1 degradation in EBV-
infected cells. C666-1 cells were treated with 25 mM ammonium
chloride, which could effectively inhibit the lysosomal degradation
pathway as demonstrated in suppressing epithelial growth factor
receptor (EGFR) degradation in serum-free C666-1 cells upon
epithelial growth factor (EGF) stimulation (Fig. 1D, right panel).
We then examined for LMP1 proteinexpression . Unlike treatment
with MG132, treatment with ammonium chloride did not result in
accumulation of LMP1 protein levels in EBV-infected cells
(Fig. 1D, left panel) suggesting that lysosomal degradation pathway
may not play a major role in regulation of LMP1 levels in EBV-
infected epithelial cells as reported by other group demonstrated
similar effects in EBV-infected B cells [14].
Id1 overexpression increases LMP1 protein levels
Previously, we have reported that LMP1 induces Id1 expression
in epithelial cells [17] which was confirmed by other independent
studies [18,19]. Given the functional relationship between LMP1
and Id1, we further examined if Id1 may regulate LMP1 protein
levels in cells. Interestingly, we observed that overexpression of Id1
resulted in increase of LMP1 proteins in the EBV-positive C666-1
cells (Fig. 2A) and HONE1 cells re-infected with EBV (Fig. 2B,
upper panel). The increase in protein is unlikely to be
transcripitonal in nature as RT-PCR examination did not reveal
increase in LMP1 transcript levels in cells subsequent to Id1
overexpression (Fig. 2B, lower panel). Furthermore, transfection of
increasing amounts of Id1 plasmid into HONE1 cells stably
expressing LMP1 (HONE1-LMP1) revealed progressive increase
of LMP1 protein in cells (Fig. 2C). In reverse, knocking down Id1
expression by shRNA in HONE1-LMP1 cells decreased LMP1
protein levels (Fig. 2D, upper panel). RT-PCR examination
confirmed that LMP1 transcript levels were not altered after Id1
knockdown (Fig. 2D, lower panel). Furthermore, immunofluores-
cence staining of LMP1 in HONE-LMP1 cells reveals that LMP1
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21176Figure 1. Proteasome inhibitor suppresses LMP1 degradation in EBV-infected epithelial cells. A, LMP1 transcript was detected in EBV-
infected cells by RT-PCR. Messenger RNA of LMP1 was detected in EBV-infected cells: HONE1-EBV (undifferentiated NPC cells) and CNE2-EBV
(undifferentiated NPC cells), HK1-EBV (differentiated NPC cells), AGS-EBV (gastric adenocarcinoma cells), C666-1 (undifferentiated NPC cells harboring
EBV) and NP460-hTERT-EBV (hTERT-immortalized human nasopharyngeal epithelial cells). TPA-treated Akata cells (Burkitt’s lymphoma cell line that
produces EBV) were used as positive control. HK1 (differentiated NPC cells), NP460-hTERT (hTERT-immortalized human nasopharyngeal epithelial
cells), Saos-2 (human osteosarcoma cell line), HaCaT (immortalized human keratinocytes) were used as negative control. The leftmost lane is the
cDNA negative control. GADPH was used as loading control. B, LMP1 protein could be detected in C666-1 cells after treatment with proteasome
inhibitor. Experiments were carried out by treating C666-1 cells with 10 mM MG132 for 8 and 16 hours before analyzed for LMP1 expression by
Western blotting. The asterisk indicates the LMP1 specific band. C, LMP1 protein accumulated in EBV-infected cells after treatment with proteasome
inhibitor. HONE1-EBV, CNE2-EBV, and NP460-hTERT-EBV cells were used in experiment. Experiments were carried out as above except the cells were
harvested after 16 hours drug incubation. D, LMP1 degradation was inhibited by proteasome inhibitor but not lysosomal inhibitor. (Left panel) C666-
1 cells were either treated with 10 mM MG132 or 25 mM ammonium chloride for 16 hours before extracted for Western blotting analysis. (Right
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together, these results suggest that Id1 expression stabilizes LMP1
protein in cells.
LMP1 interacts with Id1 via the CTAR1 domain
We further examined if LMP1 may interact with Id1 by
performing binding assay. We observed that LMP1 interacted with
Id1 and vice versa (Fig. 3A). LMP1 contains three CTAR domains
which mediates most of its downstream signaling pathways. To
further define the functional domains of LMP1 which may be
involved in the interaction with Id1, we generated LMP1 deletion
mutants with truncation of different CTAR domains. As shown in
Fig. 3B and 3C, wild type LMP1 and other truncation mutants of
LMP1 could all interact with Id1 but not the D194–233 mutant
(with deleted CTAR1) suggesting that LMP1 interacts with Id1
through the CTAR1 domain.
Id1 interacts with LMP1 via the N-terminal region
Id1 contains a potential D-box motif (RxxLxxN) at the C-
terminus [34,35,36,37] whereas the N-terminal region is impor-
tant for Id1 interacting with S5A, a subunit of 26S proteasome
[38]. We sought to identify the region(s) of Id1 that is important for
its interaction with LMP1 using Id1 deletion mutants. FLAG-
Id1DN harbors a deletion of 1–64 amino acids at the NH2
terminus, whereas the FLAG-Id-DC lacks 44 amino acids of the
COOH-terminus (Fig. 3D). Co-immunoprecipitation experiment
revealed that, while both wild type and FLAG-Id1-DC bound to
LMP1 strongly, FLAG-Id1DN could not interact with LMP1
(Fig. 3E) implying that intact N-terminal region of Id1 is essential
for Id1-LMP1 interaction.
Level of LMP1 ubiquitination correlates with the CTAR1
domain integrity
Some hints of the regulation of LMP1 degradation were
obtained by an earlier study indicating that LMP1 ubiquitination
obeys the N-end rule, i.e. instead of conjugating ubiquitin at
internal lysine residue of substrate, the ubiquitin is conjugated at
the N-terminus [14]. Mutation of CTAR1 domain resulted in
decrease of LMP1 ubiquitination [39]. These two evidences
conferred the idea that LMP1 ubiquitination may depend on the
integrity of CTAR domains. Based on these studies, we
investigated the ubiquitination status of LMP1 with mutations in
CTAR1 domain. In vivo ubiquitination assay revealed that a lower
level of polyubiquination of the CTAR1 mutant (P
2046
Q
2066T
208RAxAxA) compared to wild type LMP1 protein
(Fig. 4A). Our results support the importance of CTAR1 domain
in regulating the LMP1 polyubiquitination.
Id1 overexpression reduces LMP1 polyubiquitination
To gain insight into how Id1 stabilizes LMP1 protein in cells, we
examined if Id1 might interact and stabilize LMP1 by suppressing
its ubiquitination. We performed in vivo ubiquitination assay in
cells cotransfected with wild type LMP1 and Id1 expressing
plasmid or control vectors. As shown in Fig. 4B, Id1 overexpres-
sion reduced LMP1 ubiquitination significantly. To further clarify
the importance of Id1 in reducing LMP1 ubiquitination, we
carried out another in vivo ubiquitination experiment to check if
LMP1-Id1 interaction may affect the degree of LMP1 ubiquitina-
tion. Similar to Fig. 4A, polyubiquitination of wild type LMP1 was
relatively stronger compared to D194–233 LMP1 mutant (CTAR1
deleted mutant). Furthermore, Id1 overexpression suppressed the
polyubiquitination of wild type LMP1, but only had mild effects on
polyubiquitination for D194–233 LMP1 mutant (truncated in
CTAR1 domain) (Fig. 4C). Our results support the notion that Id1
interacts with LMP1 through the CTAR1 domain and stabilizes
LMP1 by reducing its degree of polyubiquitination.
Discussion
LMP1 is an oncoprotein of EBV encoded by the BNLF-1 open
reading frames. LMP1 expression is commonly detected in
nasopharyngeal carcinoma [6]. However, the levels of LMP1
protein detected in NPC specimens are highly variable and
heterogeneous [7]. Mechanisms of how the LMP1 protein is
regulated in EBV-infected nasopharyngeal carcinoma cells are
largely unknown.
Previous studies have reported low levels or absence of protein
expression in NPC cells [7,29,30]. In this study, we showed that
LMP1 transcription could be readily detected by RT-PCR in all
EBV-infected epithelial cells but the protein levels were either low
or absence in Western blotting analysis (Fig. 1A). The LMP1
protein levels in EBV-infected cells appeared to be tightly
regulated by proteasome-mediated proteolysis and could be
readily detected by Western blotting after treatment with
proteasome inhibitor (Fig. 1B, C). This is in agreement with an
earlier study by Aviel et al, which reported that LMP1 undergoes
ubiquitin-mediated proteolysis in an EBV-transformed lympho-
blastoid cell line stably expressing LMP1 [14]. Treatment with
ammonium chloride has minimal effects on LMP1 proteins
suggested that lysosome-mediated proteolysis, which is commonly
found in degrading transmembrane receptor, may not be a major
pathway in the degradation of LMP1 in EBV-infected epithelial
cells (Fig. 1D).
Independent studies including us have reported that LMP1
upregulates Id1 in epithelial cells [17,19,40]. Biological receptors
are known to regulate by complex signaling networks in which
feedback loops are commonly involved. Positive and negative
feedback loops have been extensively documented in various
hormonal receptors like estrogen and androgen receptor [41,42].
We sought to examine if Id1 could regulate LMP1 expression. We
observed that Id1 overexpression could indeed stabilize LMP1
protein levels in C666-1 cells which harbors EBV genome and
expresses mRNA of LMP1 (Fig. 2A, B). Furthermore, the
increased protein level of LMP1 induced by Id1 is dosage-
dependent (Fig. 2C). Conversely, Id1 knockdown results in
decrease in LMP1 (Fig. 2D). Taken together, these evidences
provide support that Id1 directly stabilize LMP1 through
mechanism that is not related to transcription.
We also showed that LMP1 could interact with Id1 in epithelial
cells (Fig. 3A). Using deletion mutants, we provided evidences that
LMP1 interacts with Id1 through the LMP1 CTAR1 domain
(Fig. 3C). We also showed that the N-terminal region of Id1 is
required to bind LMP1 (Fig. 3E). Previous study has shown that
Id1 interacts with S5A, a subunit of 26S proteasome [38]. The
interaction counteracts the inhibition of MyoD and E12 DNA
binding ability by Id1 during myogenic differentiation [43].
Several reports indicate that Id1 is targeted by APC/C-Cdh1
complex which leads to mitotic deregulation [34,35,36,37].
Binding studies further reveal that Id1 interacts with S5A via the
panel) C666-1 cells were first serum-starved for 24 hours. Cells were then either treated with PBS or 25 mM ammonium chloride for 30 minutes
before stimulated with 2 ng EGF. Cells were harvested 3 hours post-stimulation before extracted for Western blotting analysis.
doi:10.1371/journal.pone.0021176.g001
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PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21176Figure 2. Upregulation of LMP1 level in epithelial cells with Id1 overexpression. A, The levels of LMP1 protein could be detected after
overexpressing Id1 in C666-1 cells. C666-1 cells were transiently transfected either with vector alone or FLAG-Id1, and were lysed 48 hours post-
transfection. Protein were transferred to PVDF membrane and subjected to Western blot analysis with anti-LMP1 and anti-FLAG antibody. B, Increase
of LMP1 protein levels in HONE1-2117 LMP1 stable cells. HONE1-2117 LMP1 cells were transiently transfected with FLAG-Id1. Cells were examined by
Western blot analysis for LMP1 (left panel) and RT-PCR for LMP1 expression with specific primers as described under ‘‘Experimental Procedures’’ (right
panel). C, Id1 upregulated LMP1 in a dose-dependent manner. Increasing amount of Id1-HA plasmid was transfected into HONE1-2117 LMP1 which
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(RxxLxxN) at the C-terminus. The interaction between Id1 and
S5A, a subunit of proteasome; and the requirement of N-terminus
of Id1 to interact with LMP1 provide support that LMP1 may be
regulated by Id1 which correlates with proteasome-mediated
proteolysis.
We have further investigated the degree of ubiquitination of
LMP1 CTAR1 mutant when transfected into cells. Earlier findings
by Rothenberger et al. showed that the TRAF binding site –
CTAR1 was involved in regulating LMP1 protein stability [39].
We repeat the study by comparing the ubiquitination status of wild
type LMP1 and CTAR1 point mutant. In agreement with
previous study, the CTAR1 mutant is less ubiquitinated compared
to wild type LMP1. Therefore, our results reveal that the integrity
of CTAR1 domain is important in controlling LMP1 ubiquitina-
tion. Using similar approach, we determined that CTAR2 is also
involved in determining LMP1 ubiquitination (data not shown).
Future experiments are warrant to delineate the mechanism of
CTAR2 in controlling LMP1 ubiquitination.
Two pieces of information are crucial in understanding the
function of Id1 on LMP1 upregulation: (1) ubiquitin-mediated
proteolysis of LMP1 plays important role in controlling overall
LMP1 protein level, and (2) interaction between Id1 and LMP1
may influence LMP1 polyubiquitination. Id1 may interact with
LMP1 to suppress ubiquitin-mediate proteolysis of LMP1.
LMP1 is targeted to ubiquitin-mediated proteolysis, however,
the ubiquitin ligase(s) which is responsible for ubiquitin-conjuga-
tion remain unknown. The EBV latent membrane protein,
LMP2A, which contains a PY motif at the N-terminal end,
associates with HECT family of ubiquitin ligases via the WW
domain [44]. The PY motif is however, not present in LMP1.
More recently, LMP1 was found to contain one canonical and one
crytic HOS motif that can be recognized by SCF
HOS/betaTrCP E3
ubiquitin ligase [45]. However, the binding of LMP1 with
SCF
HOS/betaTrCP was shown to only affect the degree of NF-kB
activation but not LMP1 protein stability. Detail regulation of
LMP1 protein levels by ubiquitin-mediated proteasome degrada-
tion remains to be elucidated.
In summary, our study reveals a new functional link between
LMP1 levels and Id1 expression, a downstream effector of LMP1
signaling. Our results revealed a complex interplay of host cellular
proteins and EBV encoded products in EBV-infected cells.
Materials and Methods
Cell culture and transfection of genes
HEK293T, AGS, Saos-2 and HaCaT cells were obtained from
ATCC and were cultured in DMEM and F12K media supple-
mented with 10% fetal bovine serum (FBS) respectively. HONE1
cells [46], stable EBV-reinfected nasopharyngeal cancer cell lines
(HONE1-EBV and CNE2-EBV [25]), EBV-reinfected stomach
adenocarcinoma cell line (AGS) and EBV-positive nasopharyngeal
carcinoma cells (C666-1) [7] were cultured in RPMI 1640 medium
supplemented with 10% FBS [20]. NP460-hTERT cells (Immor-
talized nasopharyngeal epithelial cells expressing hTERT) [47] and
the stable EBV-infected cells were cultured in Defined-KSFM
(GIBCO) and Epilife (Gibco) in 1:1 ratio [47]. All cell lines were
maintained in 5% CO2 at 37uC. Transfection of genes into cells was
performed using Lipofectamine 2000 (Invitrogen) or Fugene HD
(Roche) following the manufacturers’ protocols.
Materials
MG132, an inhibitor of proteasome, was obtained from
Calbiochem (San Diego, CA). Primary antibodies for Id1 (C-20),
b-actin (I-19), HA-probe and Oct-A (D-8) were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibody for FLAG
(M2) was purchased from Sigma-Aldrich (Sigma-Aldrich). Antibod-
ies for LMP1 and HA (12CA5) were obtained from Dako (DAKO,
Glostrup, Denmark) and Roche (Roche, Germany) respectively.
Mouse monoclonal antibody against LMP1 (S12) was a kind gift
from Professor Jaap Middeldorp (VU University medical center,
Netherlands). Alexa-Fluor 488 and 550 conjugated secondary
antibodies were obtained from Invitrogen. HRP-conjugated sec-
ondary antibodies were from Cell Signaling Technology.
Plasmids
The construction and properties of B95.8 LMP1 prototype and
its mutants in pSG5 are described previously [17]. FLAG epitope
tag Id1 in pcDNA3/Neomycin and HA-epitope tag Ubiquitin in
pcDNA3/Zeocin were kind gifts from Dr. Patrick Ling (Queens-
land University of Technology, Australia) and Ivan Dikic (Goethe
University Medical School, Germany) respectively. Id1DN-FLAG
and Id1DC-FLAG in pcDNA3-FLAG were gifts from Karl
Mu ¨nger (Harvard Medical Schoo1, US). Id1 shRNA in pSU-
PER-Retro-Puro was gift from Joan Massague (Memorial Sloan-
Kettering Cancer Center, New York, US). Based on the FLAG
epitope tag Id1 in pcDNA3, the C-terminal HA epitope tag Id1
was constructed by PCR amplification using Based on the FLAG
epitope tag Id1 in pcDNA3, the C-terminal HA epitope tag Id1
was created was PCR amplification using forward primer 59-
GGATCCAGAAAGTCGCCAGTG-39 and reverse primer 59-
TCTAGATTACAGGCTGGCATAGTCAGGGACGTCATAA-
GGATATCAGCGACACAAGATG-39The PCR product was cut
with BamHI-XbaI and ligated into pcDNA3.
Generation of prototype B95.8 LMP1 truncation mutants
Based on the prototypeB95.8LMP1 in pSG5,theFLAG-epitope
tag B95.8 LMP1 wild type was created by PCR amplification using
forward primer 59-GGATCCATGGACTACAAAGACGAT-
GACGATAAAATGGAACACGACCTTG-39 and reverse primer
59-TTAGATTAGTCATAGTAGCTT-39; the PCR product was
cut with BamHI-XbaI and ligated into pcDNA3. Other LMP1
truncation mutants were created based on the FLAG-B95.8 LMP1
wild type in pcDNA3 by PCR amplification using the same forward
primer and specific reverse primers:
LMP1D233–386: 59-TCTAGATTAGCAGAGTGGGGGTC-
CGTC-39;
LMP1D282–386:59-TCTAGATTACTGAGGCAGCGGGT-
CATGTG-39;
stably expressed LMP1. Western blotting was performed 48 hours post transfection. The amount of plasmids used are indicated on the figure in mg.
Protein extracts were subjected to Western blot with anti-LMP1 and anti-HA antibody. Actin was used as loading control. D. Id1 knockdown was
followed by decrease of LMP1 protein level. HONE1-2117 LMP1 was transiently transfected with either scramble shRNA or Id1 specific shRNA. Cells
lysates were subjected to Western blotting analysis with anti-LMP1 and anti-Id1 antibody (left panel). RT-PCR was performed with specific primers to
detect LMP1 and ID1 gene transcripts. GADPH was used as loading control. E. Immunofluorescence examination of HONE1-2117 LMP1 cells
transiently transfected with FLAG-Id1. HONE1-2117 LMP1 cells were transfected with FLAG-Id1 plasmid and immunostained with anti-LMP1 (green),
anti-FLAG (Id1, Red) antibody and counterstained with Hoechst 33258 to locate the nucleus (see ‘‘Experimental Procedures for further details). Higher
expression of LMP1 was observed in HONE1-2117 LMP1 cells overexpressing Id1.
doi:10.1371/journal.pone.0021176.g002
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21176Figure 3. LMP1 interacts with Id1 in cells. A, HEK293 cells were transiently transfected with plasmids as shown in the figure.
Immunoprecipitation was performed as described in ‘‘Experimental Procedures’’ with either anti-FLAG or anti-HA antibody. The immunoprecipitate
was subjected to Western blot analysis with anti-FLAG (M2) and anti-HA (12CA5) antibody. B, Schematic illustration of B95.8 LMP1 and LMP1 deletion
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GGTC-39;
The PCR products were cut with BamHI-XbaI and ligated into
pcDNA3.
The C-terminal FLAG epitope tag B95.8 LMP1 wild type was
created by PCR amplification using forward primer 59-GGATC-
CATGGAACACGACCTTG-39 and reverse primer 59-TCTA-
GATTTATCGTCATCGTCTTTGTAGTCGTCATAGTAG-
CTTAGC-39.The PCR product was cut with BamHI-XbaI and
ligatedinto pcDNA3. The DN12 LMP1 was created by PCR
amplification using forward primer 59-GGATCCATGCGAC-
GGCCCCCTCGAG-39and reverse primer 59-TTAGATTAGT-
CATAGTAGCTT-39. To create the LMP1 D194–233 truncation
mutant, two PCR products were first created by forward primer
mutants used in binding experiment. C, Immunoprecipitation experiments using FLAG-B95.8 LMP1 and deletion mutants with Id1-HA. HEK293 cells
were transfected with constructs encoding the wild type and deletion mutants of LMP1 together with Id1-HA. Immunoprecipitation was performed
as described in ‘‘Experimental Procedures’’, and immunoblotting was performed using indicated antibodies. D, Schematic diagram of Id1 and deletion
mutants used in binding studies. E, Immunoprecipitation experiments using FLAG-Id1 and deletion mutants with HA-B95.8 LMP1 wild type. HEK293
cells were transfected with constructs encoding the wild type and deletion mutants of FLAG-Id1 together with HA-B95.8 LMP1 wild type.
Immunoprecipitation was performed as described in ‘‘Experimental Procedures.’’
doi:10.1371/journal.pone.0021176.g003
Figure 4. Id1 inhibits LMP1 ubiquitination in epithelial cells. A, Ubiquitination status of B95.8 LMP1 wild type and CTARs mutants in epithelial
cells. HEK293 cells were transiently transfected with plasmids as the figure shown. In vivo ubiquitination assay was performed as described in
‘‘Experimental Procedures’’ MG132 was added and cells were incubated for 6 hours before cell harvest. The extract was immunoprecipitated with
mouse monoclonal anti-LMP1 (S12) antibody and subjected to Western blot with anti-HA antibody to detect the polyubiquitin chain of LMP1 and its
mutants. B, Id1 overexpression reduced LMP1 ubiquitination. HEK293 cells were transiently transfected with plasmids as the figure shown. MG132
was added to the cells and incubated for 6 hours before cell harvest. Immunoprecipitation was performed with anti-FLAG antibody and subjected to
Western blot with anti-HA antibody to detect the polyubiquitin chain. C, Id1 binds to LMP1 and reduces LMP1 ubiquitination. HEK293 cells were
cotransfected either with wild type (WT) B95.8 LMP1 or B95.8 LMP1D194–233, with or without FLAG-Id1. Cells extracts were prepared and subjected
to immunoprecipitation followed by Western blot analysis as shown in Fig. 4B.
doi:10.1371/journal.pone.0021176.g004
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59-AGAGCAGAGTGGGGGTCCGTCATCACTGTGTCGT-
TGTCCATG-39, and forward primer 59-GACGGACCCCCA-
CTCTGCTCT-39 and reverse primer 59-TCTAGATTTATCG-
TCATCGTCTTTGTAGTCGTCATAGTAGCTTAGC-39 re-
spectively. The PCR products were mixed and amplified with
forward primer 59-GGATCCATGGAACACGACCTTG-39 and
reverse primer 59-TCTAGATTTATCGTCATCGTCTTTGT-
AGTCGTCATAGTAGCTTAGC-39. The PCR product was cut
with BamHI-XbaI and ligated into pcDNA3.
Reverse Transcription PCR (RT-PCR) analysis
RNA was extracted using Trizol (Invitrogen) according to
manufacturer’s instructions. The cDNA synthesis was performed
with the SuperScript H First-Strand Synthesis System for RT-PCR
(Invitrogen, USA), according to the manufacturer’s protocol.
Four mg of RNA was used in cDNA synthesis unless otherwise
stated. Semiquantitative PCR analysis was performed with
oligonucleotides as followed:
LMP1: forward primer: 59-TCCTCCTCTTGGCGCTACTG-
39; reverse primer: 59-TCATCACTGTGTCGTTGTCC-39,
Id1: forward primer: 59-CCGGCAAGACAGCGAGCGGTG-
CG-39; reverse primer: 59-GGCGCTGATCTCG CCGTTGAG-
GG-39
GADPH: forward primer: 59- GCCTCCTGCACCACCAAC-
TG-39; reverse primer: 59- GCCTCCTGCACCACCAACTG-39.
Western blot analysis
Whole cell lysates were extracted with RIPA buffer supple-
mented with 1: 100 protease inhibitors (Protease inhibitors
cocktail, Sigma-Aldrich). Protein concentration was determined
by Bio-Rad DC Protein assay. Protein was boiled in SDS-sample
buffer for 5 minutes and electrophoresed on 7.5 to 12.5%
polyacrylamide gels, and transferred onto PVDF membrane.
Non-specific reactivity was blocked with either 1% BSA or 4%
non-fat dry milk in TBST for 1 hour. The membrane was
incubated with primary antibodies according to the manufactur-
ers’ instructions. The membrane was washed with TBST and
incubated with HRP-conjugated secondary antibodies for 1 hour,
and washed three times with TBST for 30 minutes. The
perioxidase activity was detected by ECL plus solution (Amer-
sham) and exposed to light-sensitive films (GE Healthcare, USA).
The films were processed with developer and fixer to get the
images (Kodak, USA).
Immunoprecipitation studies
For the interaction studies of Id1 and LMP1, 400 mg of cell
lysates were incubated with primary antibodies for 2 hours. And
the immunoprecipitates were recovered by incubating with
Protein A agarose beads (Thermos, USA) for 1 hour. The beads
were washed three times with lysis buffer and boiled with 26SDS-
sample buffer for 10 minutes before subjecting to electrophoresis.
In vivo Ubiquitination Assays
Cells were transfected with 0.5 mg of HA-Ubiquitin plasmid and
1 mg of LMP1 plasmid. To accumulate the polyubiquitinated
protein, cells were treated with 10 mM MG132 for 6 hours before
cell harvesting. Whole cell lysates were extracted with RIPA buffer
supplemented with protease inhibitors. 250 mg of cell lysates were
incubated with primary antibodies for 2 hours. And the
immunoprecipitates were recovered by incubating with Protein
A agarose beads (Thermos, USA) for 1 hour. The beads were
washed three times with lysis buffer and boiled with 26 SDS-
sample buffer for 10 minutes before subjecting to electrophoresis.
Immunofluorescence studies
Cells were washed in PBS and incubated in 4% paraformal-
dehyde for 15 minutes. Cells were then permeabilized and blocked
in solution with 0.1% triton X-100 and 3% BSA for 30 minutes in
room temperature. Cells were washed 1 time with PBS and
incubated with primary antibodies for 1 hour. Samples were then
washed three times with PBS before incubating with secondary
antibodies for 1 hour. Cells were counterstained with Hoechst
33258 to visualize the nuclei. The coverslips were mounted on
glass slides with fluorescence mounting medium (Dako, Glostrup,
Denmark) and visualized using a Carl Zeiss epi-fluorescence
microscope.
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